In vivo selection may provide a means to increase the relative number of cells of donor origin in the setting of hemopoietic chimerism. We have tested whether in vivo selection using chemical inducers of dimerization (CID) can direct the expansion of transduced normal donor erythrocytes in the setting of chimerism using a mouse model of pyruvate kinase deficiency. Marrow cells from normal CBA/N mice were transduced with a vector (F36Vmpl) that promotes cell growth in the presence of CID. Transduced cells were then transplanted into minimally conditioned, pyruvate kinase deficient, recipients (CBA-Pk-1 slc /Pk-1 slc ) to establish stable chimerism. CID administration resulted in expansion of normal donor erythrocytes and improvement of the anemia. The preferential expansion of normal erythrocytes also resulted in a decrease in erythropoietin levels, reducing the drive for production of pyruvate kinase deficient red cells.
Abstract
In vivo selection may provide a means to increase the relative number of cells of donor origin in the setting of hemopoietic chimerism. We have tested whether in vivo selection using chemical inducers of dimerization (CID) can direct the expansion of transduced normal donor erythrocytes in the setting of chimerism using a mouse model of pyruvate kinase deficiency. Marrow cells from normal CBA/N mice were transduced with a vector (F36Vmpl) that promotes cell growth in the presence of CID. Transduced cells were then transplanted into minimally conditioned, pyruvate kinase deficient, recipients (CBA-Pk-1 slc /Pk-1 slc ) to establish stable chimerism. CID administration resulted in expansion of normal donor erythrocytes and improvement of the anemia. The preferential expansion of normal erythrocytes also resulted in a decrease in erythropoietin levels, reducing the drive for production of pyruvate kinase deficient red cells.
CID-mediated expansion of genetically modified erythrocytes could prove a useful adjunct to transplant methods that achieve erythroid chimerism.
Introduction
While many inherited blood disorders are curable via stem cell transplantation, the applicability of the procedure is limited in part by its toxicity. One way to reduce the toxicity associated with stem cell transplantation is through the use of attenuated conditioning regimens that fall short of producing complete myeloablation, and lead to the establishment of donor/host chimerism.
Studies in inherited red cell disorders have shown that relatively small percentages of normal donor cells can substantially ameliorate the severity of these diseases. Individuals who have developed chimerism following stem cell transplantation for -thalassemia or sickle cell disease demonstrate that as few as 10% of normal donor progenitors can functionally compensate for the anemia that characterizes these disorders [1] [2] [3] . Similar conclusions pertain to the relevant mouse models of these disorders [4] [5] [6] [7] [8] [9] .
However chimerism alone does not correct all of the manifestations of hemolysis.
Transplantation studies in a sickle cell mouse model demonstrated that hematologic and pathologic correction required 100% peripheral red blood cell chimerism 10 . In studies of hematopoietic chimerism in a dog model of pyruvate kinase (PK) deficiency, improvement in the anemia failed to eliminate persistent hemolysis in one animal resulting in severe iron overload and cirrhosis 11 . Following stem cell transplantation for thalassemia, persistent iron overload is treated with aggressive phlebotomies to forestall progression of liver fibrosis 12 . However, patients with chimerism may not tolerate phlebotomy due to low hematocrits, mandating treatment with chelation therapy 3, 13 . Methods that would allow for the erythropoietin independent expansion of donor-origin erythropoiesis may suppress erythropoietin production
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We have previously described a system that uses small molecule drugs as artificial growth factors for genetically modified cells. These drugs, called chemical inducers of dimerization (CIDs), exert their activity by directing the self-association of hybrid signaling molecules composed of a CID binding domain and the intracellular portion of a growth factor receptor 15, 16 .
We have shown that CID-mediated activation of the intracellular portion of the thrombopoietin 
Methods
Retroviral vector -The retroviral vector, F36Vmpl GFP , has been described in a previous publication 18 . Briefly, this vector is based on MSCV 23 and expresses a single transcript that encodes the CID responsive cytoplasmic portion of the thrombopoietin receptor (mpl) and the enhanced green fluorescent protein (GFP) (Figure 2 A) . A stable ecotropic producer line (GP+E86) with a titer of 1 x 10 6 was employed for co-culture based gene transfer.
Mice
Breeding pairs of the wild-type strain, CBA/N, and the pyruvate kinase mutant strain, CBA-Pk-1 slc /Pk-1 slc , were obtained from the SLC facility in Japan 21 . They were maintained in a specific pathogen free facility. In addition the animals were maintained on a breeder diet to limit the possibility of developing folate deficiency.
Gene Transfer and Transplantation
Twelve-to 16-week-old donor mice were treated with 150 mg/kg 5-fluorouracil (5-FU) by intraperitoneal (IP) injection 2 days before bone marrow mononuclear cells were harvested.
Cells were pre-stimulated for 48 hours in Dulbecco's minimal essential medium containing 16% fetal calf serum (FCS), 5% IL-3-conditioned medium, 100 ng/mL recombinant human IL-6, and 50 ng/mL recombinant murine stem cell factor (SCF) in a 37°C, 5% CO2 incubator. Cells were then transferred onto irradiated (1500 cGy) producer cells and co-cultivated using identical growth conditions except for the addition of polybrene (8 µg/mL). Marrow cells were harvested after 48 hours and immediately infused via tail vein injection. Eight-to 12-week-old recipient mice received variable dose of radiation from a dual cesium 137 gamma source (GammaCell 40, AEC, Kanata, ON, Canada) before infusion of between 2 to 10 × 10 6 transduced bone marrow.
Gene transfer was monitored by plating in methylcellulose and scoring progenitor colonies for
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AP20187 administration
The drug used to regulate cell expansion was AP20187 (ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, USA). This drug was designed to specifically bind to two mutated FK1012 binding proteins (FKBP). A point mutation was introduced into the FKBP domain that changed a phenylalanine to valine resulting in decreased binding to endogenous FKBPs 19, 24 . This is the F36V portion of the mpl fusion protein. Lyophilized AP20187 was solubilized in 100% ethanol to produce a 5-mg/ml stock that was stored at -20 °C. From this stock solution AP20187 was diluted fresh on the day of injection. The final solution for injection contained 10% PEG 400 and 1.4% Tween80. We administered AP20187 by daily intraperitoneal injection in a total volume of 400 µl per injection.
Hematologic Parameters
Red cell number, reticulocyte percentage, red cell and platelet GFP expression were determined every one to two weeks via a 10 µl sample of blood taken from a tail vein. Red cell numbers were determined on a Coulter Z series after a 1 to 50,000 dilution in isotonic saline. CBA-Pk-1 slc /Pk-1 slc mice were conditioned with either 100 cGy or 400 cGy of gamma irradiation in a single dose on the day of transplantation (schematic, Figure 2B ). Further analysis of the six surviving animals at 67 weeks post transplant is presented as supplemental data. However, conclusions related to toxicity are limited given the small numbers of experimental animals.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Lack of CID response in leukocytes. We also examined whether CID administration expanded transduced peripheral blood leukocytes. Due to the relatively large volume of blood required for these studies, the evaluation of leukocytes was performed only after demonstrating a clear effect of CID treatment on red cells. Retro-orbital blood sampling was performed on the mice presented in Figure 4 at week 44. DNA was purified from the leukocytes. PCR was performed using primers that flank the mutation responsible for the enzyme deficiency. The mutation results in the loss of a BstE II restriction enzyme site, allowing the determination of donor leukocyte contribution (Figure 6 A) . Resulting bands were separated on an agarose gel and band intensity was determined (Figure 6 B) . The average of the donor contribution in CID-treated and untreated mice is shown in the bar graph in Figure 6 C. Donor contribution in untreated mice was 6.13% and in treated mice was 9.16%. This difference was not significant (p=0.28).
Leukocytes were also examined for GFP expression by flow cytometry. There was no significant difference in the proportion of either neutrophils or lymphocytes that expressed GFP between the treated and untreated groups (Figure 6 D) . Unlike previous findings in the dog transplant model 19 , lymphocyte expansion was not observed.
Discussion
A new approach to cell therapy aims to identify methods to specifically control the fate of transplanted cells 33 . Hemopoietic growth factors provide a means for controlling cell growth in vivo. However growth factors lack the ability to selectively expand a subpopulation of genetically-modified cells within a particular hemopoietic lineage. Selectivity can be achieved by first engineering cells ex vivo so their fate can be controlled in vivo using exogenously supplied small molecules. We have developed a means whereby cell expansion can be directed using CIDs 16 . This approach could be advantageous in the setting of gene therapy in which only a fraction of cells contain the therapeutic gene, or in nonmyeloablative transplants, when donor and host hemopoietic elements coexist.
In the studies outlined above, selective expansion of normal donor erythrocytes with normal pyruvate kinase activity resulted in improvements in the anemia of the recipient mice. In this setting, the CID functions a manner analogous to erythropoietin, targeting erythroid cells expressing the F36Vmpl fusion protein. Much like the use of growth factors, the dose of CID can be adjusted to achieve the desired level of red cell production ( Figure 4E ). The combination of reduced intensity conditioning followed by repeated administrations of CID was well tolerated by the CBA-Pk-1 slc /Pk-1 slc mice. A concern with repeated administrations of the CID was that depletion of transduced progenitors would occur. An initial resistance to CID-mediated expansion in some mice was overcome with more frequent administration of CID. This resulted in a median red cell number in the normal range for the 5 treated mice. In fact, 2 of the CIDtreated mice developed erythrocytosis with red blood cell numbers greater than 13 x 10 9 RBCs/ml, necessitating a pause in CID treatment. We monitored transplanted mice for the However, drug resistance genes have encountered two types of obstacles. First, stem cells and progenitors are relatively resistant to many cytotoxic drugs, resulting in relatively limited in vivo efficacy for drug resistance genes such as dihydrofolate reductase [37] [38] [39] and MDR1 40, 41 . Second, the drugs used to achieve selection harbor very considerable hematological and nonhematological toxicities 39, 42, 43 . In addition to immediate toxicities, the mutagenicity of many cytoxic agents, most notably alkylating drugs used in association with methylguanine methyltransferase (MGMT), adds a very significant burden of secondary malignancies, especially leukemias 44, 45 .
Compared to selection using chemoprotectant proteins, CID-dependent expansion is reversible and does not require the systemic administration of DNA damaging agents. However, limiting the proliferative response to the progeny of transduced stem cells would require continuous CID administration in order to maintain the therapeutic effect. Leukemia is generally thought to originate in cells with an unlimited capacity for self-renewal, such as B cells, T cells, and hemopoietic stem cells 46 . Based upon this principle, directing a growth signal to cells with a limitless capacity for self renewal may raise a greater concern for the development of leukemia than if the growth signal were confined to committed progenitors, which are generally considered to have a finite capacity for self-renewal. This view is supported by the abundance of clinical safety data that exists for chronically administered growth factors such as erythropoietin, GM-CSF and G-CSF 47, 48 . While the requirement for ongoing CID administration constitutes an inconvenience and harbors the risk of long-term drug exposure, the ability to withdraw selection may provide a crucial safety valve if leukemia were to occur. Testing for the development of leukemias in mice treated with CID may require performing secondary transplants, similar to previous reports of leukemogenesis in mouse transplant models 34 .
This method could be applied as adjunct therapy to both gene transfer based therapies for erythrocyte disorders as well as transplant strategies aimed at establishing mixed chimerism.
Improvements to this approach will include the use of erythrocyte specific promoters such as spectrin or ankyrin to limit expression of the selectable protein to erythroid progenitors [49] [50] [51] . In addition, we are testing other signaling molecules including the JH1 domain of Jak2 that may provide a more selective signal for directing red cell expansion (manuscript submitted). The combination of reduced intensity conditioning with in vivo selection could prove useful for eventual gene therapy for the erythrocyte disorders 32 . For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
